Ibandronate Versus Placebo in the Prevention of Bone Loss After Renal Transplantation.
Status:
Unknown status
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
Loss of bone mass is a common complication in patients with end-stage-renal failure, both
before and particularly after transplantation. In addition to standard underlying therapy
with calcium and active vitamin D, we will study the effect of ibandronate (a bisphosphonate)
versus placebo on bone mineral density as well as incidence of fracture rates after kidney
transplantation.We also wish to study whether any prevented bone loss will also lead to
reduced cardiovascular disease. Patients will be followed for 12 months after
transplantation, and the ibandronate treatment is one injection every 3 months.